Objective-In the general population, lipoprotein(a) [Lp(a)] has been established as an independent causal risk factor for cardiovascular disease. Lp(a) levels are to a major extent regulated by a size polymorphism in the apolipoprotein(a) [apo(a)] gene. The roles of Lp(a)/apo(a) in human immunodeficiency virus (HIV)-related elevated cardiovascular disease risk remain unclear. Approach and Results-The associations between total plasma Lp(a) level, allele-specific apo(a) level, an Lp(a) level carried by individual apo(a) alleles, and common carotid artery intima-media thickness were assessed in 150 HIV-infected and 100 HIV-uninfected women in the WIHS (Women's Interagency HIV Study). Linear regression analyses with and without adjustments were used. The cohort was young (mean age, ≈31 years), with the majority being Blacks (≈70%). The prevalence of a small size apo(a) (≤22 Kringle repeats) or a high Lp(a) level (≥30 mg/dL) was similar by HIV status. Total plasma Lp(a) level (P=0.029) and allele-specific apo(a) level carried by the smaller apo(a) sizes (P=0.022) were significantly associated with carotid artery intima-media thickness in the HIV-infected women only. After accounting for confounders (age, race, smoking, body mass index, blood pressure, hepatitis C virus coinfection, menopause, plasma lipids, treatment status, CD4 + T cell count, and HIV/RNA viral load), the association remained significant for both Lp(a) (P=0.035) and allele-specific apo(a) level carried by the smaller apo(a) sizes (P=0.010) in the HIV-infected women. Notably, none of the other lipids/lipoproteins was associated with carotid artery intima-media thickness. Conclusions-Lp(a) and allele-specific apo(a) levels predict carotid artery intima-media thickness in HIV-infected young women. Further research is needed to identify underlying mechanisms of an increased Lp(a) atherogenicity in HIV infection. Visual Overview-An online visual overview is available for this article. 10 Lp(a) levels vary across ethnicity/race, with the most profound differences between populations of African versus non-African (eg, European) descents. [13] [14] [15] Further, carriers of smaller apo(a) isoforms (≤22 K4 type 2 repeats) have a 2-fold higher risk of coronary heart disease or ischemic stroke than noncarriers.
I ndividuals infected with human immunodeficiency virus (HIV) are at significantly increased risk for cardiovascular disease (CVD) compared with uninfected individuals. [1] [2] [3] HIV infection is associated with a 50% to 100% greater risk of CVD beyond that explained by traditional risk factors, such as hypertension, smoking, and cholesterol level. 4 In a cohort without traditional CVD risk factors, the risk for acute myocardial infarction was 2-fold higher in HIV-infected individuals compared with that in HIV-uninfected individuals. 5 In a meta-analysis, HIV, treatment status and type, and disease activity were associated with CVD risk. 3 Taken together, these findings point out the presence of a significant deficit in the understanding of HIV-related excess CVD risk and the need to identify more contributing factors.
In the general population, an elevated level of plasma lipoprotein(a) [Lp(a)] is established as an independent causal risk factor for CVD and recognized in clinical guidelines. [6] [7] [8] [9] Lp(a) levels are to a major extent regulated by genetics, where a size polymorphism in the apolipoprotein(a) [apo(a)] gene accounts for the majority of the genetic variability in Lp(a) level. 10 Apo(a), a key structural component of Lp(a), consists of repeated loop structures, termed Kringles (K); one of these K motifs (ie, K4 type 2) exists in multiple copies. 11, 12 In general, smaller apo(a) sizes with fewer K4 type 2 repeats are associated with higher plasma Lp(a) levels. 10 Lp(a) levels vary across ethnicity/race, with the most profound differences between populations of African versus non-African (eg, European) descents. [13] [14] [15] Further, carriers of smaller apo(a) isoforms (≤22 K4 type 2 repeats) have a 2-fold higher risk of coronary heart disease or ischemic stroke than noncarriers. 16 Despite these advances in the general population, less is known about the roles of Lp(a) level and apo(a) size polymorphism in HIV-related CVD development.
In the general population, we previously demonstrated that the allele-specific apo(a) level (ASL), an Lp(a) level associated with a defined apo(a) isoform size for a given individual, can inform coronary heart disease risk assessment. 17 In a subsequent study in an HIV-infected population, we showed an increase in the ASL carried by smaller apo(a) sizes in a group with improved disease status. 18 Because the extent of association between a risk factor and disease might vary by HIV status, we investigated the ability of Lp(a) and ASLs to predict carotid artery intima-media thickness (cIMT) in HIVinfected women enrolled in the WIHS (Women's Interagency HIV Study). We further tested the effects of HIV treatment status on the associations of Lp(a) or ASLs with cIMT.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Characteristics of Study Population
The mean age was ≈31 years (age range, 21-37 years), and the cohort predominantly consisted of Blacks (≈70%; Table 1 ). HIV-infected women had a lower body mass index (P=0.045) and a higher diastolic blood pressure (BP; P=0.029) compared with HIV-uninfected women. Among the HIV-infected women, 37% had a CD4 + T cell count <350 cells/mm 3 . Further, 39% of all HIV-infected women had an HIV RNA viral load below or at the lower detection limit (ie, 80 copies). The average duration of HIV infection was 8.7±3.5 years. The use of medications for heart disease, hypertension, or diabetes mellitus was low, regardless of HIV status (2%-4%). Among the HIV-infected women, 11 women (7%) reported any type of statin use. The rate of current smokers was high (41% and 33% in the HIVinfected and HIV-uninfected groups, respectively). The majority of women (≈97%) were free of hepatitis C virus coinfection. HIV-infected women had a significantly lower high-density lipoprotein cholesterol (HDL-C; P<0.0001) and a higher triglyceride (P<0.0001) level compared with HIV-uninfected women ( Table 1 ). The mean cIMT was significantly lower in the HIV-infected versus HIV-uninfected groups (645±70 versus 670±80 µm, respectively; P=0.014), and only 1 HIV-infected and 2 HIV-uninfected women had a presence of carotid lesions.
Of the HIV-infected women, about half (51%, n=76) were on treatment, with 73 women (96%) receiving highly active antiretroviral therapy (ART), 2 (2.6%) receiving combination therapy, and 1 (<1%) receiving monotherapy. Among those on highly active ART, 44 (60%) women were on protease inhibitor-based regimens and 29 (40%) women were on nonnucleoside reverse transcriptase inhibitor-based or nucleoside reverse transcriptase inhibitor-based regimens. Treated HIVinfected women were slightly older and had a lower body mass index compared with untreated HIV-infected women. 
Lp(a) and ASLs and Apo(a) Phenotypes
The median total plasma Lp(a) level (19 versus 25 mg/dL; P=0.024) and ASL carried by the smaller apo(a) sizes (14 versus 19 mg/dL, P=0.037) were significantly lower in the HIV-infected versus HIV-uninfected women (Table 2; Figure  I in the online-only Data Supplement). The frequency of a high Lp(a) level (≥30 mg/dL) was 32% and 43% in the HIVinfected and HIV-uninfected groups, respectively. The difference across HIV status for the prevalence of a high Lp(a) level (≥50 mg/dL) reached a borderline significance (17% versus 27% for the HIV-infected and HIV-uninfected groups, respectively; P=0.057). As expected, the majority of individuals had 2 detectable apo(a) protein bands (>70%). The distribution pattern of apo(a) phenotypes (ie, single or double) did not differ significantly by HIV status, and the median sizes for the larger or smaller apo(a) isoforms were similar in the HIV-infected and HIV-uninfected groups (Table 2 ). Among individuals with double apo(a) protein bands, the majority had a co-dominating (41%) or a smaller dominating (≈50%) pattern, and the distribution pattern of apo(a) dominance did not differ significantly by HIV status. In both HIV-infected and HIV-uninfected groups, ≈18% of women had a small size apo(a) (≤22 K).
Analyses among HIV-infected women across treatment status revealed no significant differences in total plasma Lp(a) and ASLs, frequency of high Lp(a) level or a small size apo(a), and distribution patterns of apo(a) phenotypes or dominance between treated and untreated group ( 
Associations of cIMT With Clinical Variables
As expected, age was a significant predictor of cIMT in both HIV-uninfected (P<0.0001) and HIV-infected (P=0.0007) groups (Table 3 ). In addition, CD4 + T cell count (P=0.033) in the HIV-infected group and systolic BP (P=0.0002) and glucose (P=0.002) in the HIV-uninfected group were significantly associated with cIMT. However, none of the major lipids and lipoproteins was significantly associated with cIMT (Table 3) . Data are presented as mean±standard deviation or number (%), except for triglycerides which are given with median (interquartile range). BP indicates blood pressure; cIMT, carotid intima media thickness; HCV, hepatitis C virus; HAART, highly active antiretroviral therapy; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
*The treated HIV + group included 73 subjects on HAART, 2 subjects on combination therapy, and 1 subject on monotherapy. May 2017 
Associations of cIMT With Lp(a) Level or ASLs
Effect of HIV Treatment Status on the Associations of cIMT With Lp(a) Level or ASLs
We further examined the impact of HIV treatment status on the associations of cIMT with total plasma Lp(a) level or ASLs in HIV-infected women. We observed a significant correlation of Lp(a) level with cIMT in the treated HIV-infected women (β=0.00775; 95% CI, 0.00156-0.01392; P=0.015), but not in untreated HIV-infected women (β=0.00247; 95% CI, −0.00526 to 0.01021; P=0.528; Table 4 ; Figure I in the online-only Data Supplement). Similarly, ASL carried by the smaller apo(a) size was significantly associated with cIMT in the treated group only (β=0.00091; 95% CI, 0.00012-0.00170; P=0.025). In a model adjusted for potential confounders (age, ethnicity/race, current smoking, body mass index, BP, hepatitis C virus coinfection, menopause, LDL cholesterol, HDL-C, triglycerides, CD4 + T cell count, and HIV RNA viral load), both total plasma Lp(a) level (β=0.00696; 95% CI, 0.00054-0.01338; P=0.036) and ASL carried by the smaller apo(a) size (β=0.00101; 95% CI, 0.00019-0.00183; P=0.018) remained significantly associated with cIMT in the HIV-infected treated group. 
Discussion
This is the first study to examine the associations of Lp(a) level and ASLs with cIMT in relation to apo(a) isoform sizes and HIV treatment status. The major novel findings in this study of HIV-infected and HIV-uninfected young women are (1) significant associations of Lp(a) level or ASLs carried by the smaller apo(a) sizes with cIMT were observed in the HIVinfected group, but not in the HIV-uninfected group; and (2) an impact by HIV treatment status on the association of Lp(a) level or ASL carried by the smaller apo(a) sizes with cIMT was seen. Notably, adjustments for covariates did not alter the significant associations of Lp(a) or ASLs with cIMT in the HIV-infected group. Furthermore, there were no significant differences in the frequency of high Lp(a) level or small size apo(a) (≤22 K) and distribution patterns of apo(a) expression or apo(a) dominance across HIV or treatment status.
HIV-infected individuals are at significantly elevated risk of atherosclerosis and CVD compared with HIV-uninfected individuals. [1] [2] [3] Infection with HIV causes persistent immune activation associated with CD4 + T cell loss, HIV RNA viral load, and disease progression, as well as several significant anthropometric and metabolic alterations, including dyslipidemia. 19 While HIV/ART-induced modifications in lipids and lipoproteins and their relationships with CVD have been investigated previously, 20 documentation of any role of plasma Lp(a) level and genetic variability in the apo(a) gene (eg, a size polymorphism) in HIV-related elevated CVD risk is lacking. A small longitudinal study reported an increase in Lp(a) level from baseline among protease inhibitor-treated HIV-infected individuals. 21 In a previous study among HIV-infected individuals, we found an elevated ASL carried by the atherogenic smaller apo(a) size in the group with an improved HIV disease status. 18 This observation suggested that although considered as one of the most heritable quantitative traits in humans, 10 Lp(a) level and associated risk factor properties can be modulated by HIV disease status, a clinically relevant nongenetic BMI indicates body mass index; BP, blood pressure; cIMT, carotid intima media thickness; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; and TG, triglycerides. *A P value <0.05 indicates a significant correlation of cIMT with the variable within the group. Conversely, a P value >0.05 for a variable indicates that there is no significant correlation of that variable with cIMT within the group.
factor, and thus may potentially contribute to the high CVD risk seen in HIV-infected individuals. In the current study, despite a lower Lp(a) level and a comparable distribution of apo(a) isoforms in the HIV-infected versus HIV-uninfected group, cIMT was associated with Lp(a) level only in the HIVinfected group. Similarly, ASLs for smaller apo(a) sizes were lower in the HIV-infected versus HIV-uninfected group, but were associated with cIMT in the HIV-infected group. These findings suggest that HIV may play a modulatory role independent of apo(a) size polymorphism and that HIV-specific mechanisms are contributing to enhance Lp(a) atherogenicity. It is tempting to speculate that the high frequency of untreated HIV-infected women may have contributed to the overall lower Lp(a) level seen in the HIV-infected group.
In several of our previous studies in the general population, we demonstrated a significant positive association between metabolic abnormalities assessed by elevated levels of systemic and vascular inflammatory biomarkers and Lp(a) level or ASLs. [22] [23] [24] HIV-induced persistent immune activation and heightened inflammation have been associated with increased premature age-related comorbidities, including CVD, in HIVinfected individuals. [25] [26] [27] [28] With the use of ART inflammatory burden declines, however, inflammatory biomarkers remain high compared with those in HIV-uninfected individuals. [29] [30] [31] It is tempting to speculate that this residual post-ART higher burden of metabolic disturbance promotes Lp(a) atherogenicity in the setting of HIV infection. Furthermore, in the circulation, proinflammatory and proatherogenic oxidized phospholipids bind to Lp(a) with a substantially greater affinity than other plasma lipoproteins. 32 Thus, the increased Lp(a) atherogenicity in the context of HIV may be mediated, in part, by its role as being a preferential carrier of proinflammatory and proatherogenic oxidized phospholipids. Indeed, although data are lacking with regards to Lp(a)-oxidized phospholipids, HIV infection was associated with elevated levels of oxidized LDL, which were also correlated with biomarkers of monocyte activation. 33 Thus, further investigations directly assessing the roles of Lp(a)-oxidized phospholipids or post-ART residual inflammatory burden in mediating Lp(a)-associated elevated CVD risk in the setting of HIV are warranted.
In agreement with other studies, HIV was associated with a lower HDL-C and a higher triglyceride level. 19 However, total cholesterol and LDL cholesterol levels were comparable across HIV status. Notably, in our cohort, none of these lipids and lipoproteins predicted cIMT in HIV-infected or HIVuninfected women. In our cohort with a mean age of ≈31 years, cIMT was lower in the HIV-infected versus HIV-uninfected group. Consistent with these findings, a recent pooled analysis of 5 cohorts reported a lower cIMT value in the HIV-infected versus HIV-uninfected group in the age range of 30 to 49 years (50% women in the HIV-infected group). 34 Being a genetically regulated heritable trait, as opposed to traditional risk factors susceptible to lifestyle modifications or drug interventions, Lp(a) presents a unique setting where individuals with an elevated level or carriers of an atherogenic small size apo(a) are exposed to a high CVD burden over the entire course of their lifespan. Among HIV-infected individuals, the association of cIMT with traditional determinants of CVD burden, such as higher systolic BP or lower HDL-C, was strengthened with age. 34 This observation, together with our Lp(a) findings in young HIV-infected women, suggest that the effect of HIV on carotid artery structure may differ across the lifespan with HIV-specific mechanisms or novel factors [eg, Lp(a)] may be playing a greater role in HIV-infected younger adults than in older adults. In a slightly older cohort of the WIHS (mean age, ≈42 years), LDL cholesterol and non-HDL-C levels were significantly and positively associated with cIMT in ART-treated HIV-infected women, but not in the untreated HIV-infected women. 35 Further, the significant association between these lipids and cIMT in the ART-treated HIV-infected women appeared to be weaker than those observed in the HIV-uninfected women. 35 Taken together, these findings indicate that the relationship of atherogenic and antiatherogenic lipids with atherosclerotic processes in the HIV setting is a complex process and that the ability of these lipoproteins to predict cardiovascular risk may evolve over the course of HIV infection. Evidence further indicates that atherosclerotic processes start in early childhood, progressing with age, and that this process begins even prematurely among HIV-infected children and young adults. 36, 37 Notably, the global impact of HIV disease and its treatment on Lp(a)-associated CVD risk may be substantial in that (1) the majority of people with HIV live in sub-Saharan Africa, and increasing numbers will be treated with antiretroviral treatment; (2) people of African ancestry have on average 2 to 3 times greater Lp(a) levels compared with those of non-African ancestry. Moreover, in the United States, data also indicate that HIV infection disproportionally affects ethnic minorities, in particular, young Blacks. Collectively, these facts highlight the importance of Lp(a)/apo(a) to increase CVD risk in HIV-infected individuals in the era of highly active ART and open possibilities for a targeted intervention to reduce overall CVD risk in this vulnerable population.
We acknowledge some limitations of our study. First, our results are based on a cross-sectional assessment of the relationship between Lp(a) and cIMT in a women-only, relatively young HIV-infected cohort. Further longitudinal studies in HIV-infected women, as well as in HIV-infected men, and across the lifespan (children, adolescents, and older adults) are needed to confirm this relationship. Second, the cohort consisted of mainly Blacks; there is a need to extend this observation to other racial/ethnic groups. Third, although we found a significant association between cIMT and Lp(a) in HIV-infected women on treatment, we were unable to address a possibility of differential impact by various treatment regimens. Fourth, although considered as a well-established indicator of future CVD risk, cIMT may not fully capture the complexity of HIV/highly active ART-induced deleterious effects on vascular structure. Studies with available data on carotid 3-dimensional imaging or carotid plaque volume determined by magnetic resonance imaging in HIV-infected populations may provide valuable information.
In conclusion, elevated levels of Lp(a) or allele-specific apo(a) carried by the smaller apo(a) sizes are associated with cIMT in HIV-infected young women. Further research is needed to identify underlying mechanisms of an increased Lp(a) atherogenicity in the setting of HIV infection. A disease biomarker that has the potential to remain informative over the course of lifespan because of its high heritability and relative resistance to interventions may support clinicians in their efforts to identifying HIV-infected individuals at increased risk for CVD, regardless of the stages of lifespan or HIV infection.
